SQZ News and Press, SQZ Biotechnologies Company From 07/12/22

ESMO Immuno-Oncology and Technology Article Details Importance of Intracellular Delivery to Drive Effective MHC-I Mediated Activation of CD8 T Cells Paper Highlights Preclinical SQZ ® APC Combination Data with PD-1 IL2v and Manufacturing Benefits of the Cell S...

SQZ Biotechnologies ( NYSE: SQZ ) announced Monday the promotion of Micah Zajic to the role of company's chief financial officer, effective immediately. Zajic has served as the company’s chief business officer since October 2020 and brings nearly two decades of...

Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for...

SQZ ® TACs Result in the In Vitro Presentation of Antigen Associated with Celiac Disease, Supporting T Cell Tolerizing Approach Cell Squeeze ® Process Leads to TACs with Consistently High Amounts of Antigen Cargo Findings Build on Published Type 1 Diabetes TAC ...

Pre-Clinical Research Could Lead to Rapid Development of Dopamine-Producing Neurons; Part of Company’s NIH-Funded Program Seeking Scalable Cell Replacement Therapy Approaches for Parkinson’s Disease Use of Non-Viral, Self-Amplifying RNA Enhanced and Lengthened Tr...

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compou...

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on Jun...

SQZ Biotechnologies (NYSE:SQZ) has appointed Marshelle Smith Warren as chief medical officer, effective June 1. She was previously CMO and SVP, R&D at Viracta Therapeutics (VIRX). She has also served as a senior advisor clinical research programs for investigational T cell therapies ...

Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1 st , 2022 SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of c...

The following slide deck was published by SQZ Biotechnologies Company in conjunction with this event. For further details see: SQZ Biotechnologies (SQZ) Investor presentations - Slideshow